Survey of current trends in the abuse of psychotropic substances and plants in Japan

Legal Medicine

Volumn 13, Issue 3, 2011, Pages 109-115

  Kikura Hanajiri, Ruri ^a   Uchiyama, Nahoko ^a   Goda, Yukihiro ^a  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

Cathinone derivatives; Designer drugs; Psychotropic plants; Synthetic cannabinoids

Indexed keywords

CANNABINOID DERIVATIVE; CATHINONE; PSYCHOTROPIC AGENT;

DRUG ABUSE; DRUG CLASSIFICATION; DRUG MARKETING; HUMAN; INTERNET; JAPAN; LAW; PLANT; REVIEW; SUBSTANCE ABUSE;

CANNABINOIDS; HUMANS; JAPAN; LEGISLATION, DRUG; PLANTS, MEDICINAL; PSYCHOTROPIC DRUGS; SUBSTANCE-RELATED DISORDERS;

EID: 79952738736     PISSN: 13446223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.legalmed.2011.02.003     Document Type: Review

References (72)

1. Nagashima M., Seto T., Takahashi M., Miyake H., Yasuda I. Screening method of the chemical illegal drugs by HPLC-PDA. Ann Rep Tokyo Metr Inst Pub Health 2004, 55:67-71.
2. Kikura-Hanajiri R., Hayashi M., Saisho K., Goda Y. Simultaneous determination of 19 hallucinogenic tryptamines/ß-calbolines and phenethylamines using GC-MS and LC-ESI-MS. J Chromatogr B 2005, 825:29-37.
3. Seto T., Takahashi M., Nagashima M., Suzuki J., Yasuda I. The identifications and the aspects of the commercially available uncontrolled drugs purchased between Apr. 2003 and Mar. 2004. Ann Rep Tokyo Metr Inst Pub Health 2005, 56:75-80.
4. Suzuki J., Takahashi M., Seto T., Nagashima M., Okumoto C., Yasuda I. Qualitative method of nitrite inhalants. Ann Rep Tokyo Metr Inst Pub Health 2006, 57:115-120.
5. Matsumoto T., Kikura-Hanajiri R., Kamakura H., Kawamura N., Goda Y. Identification of N-Methyl-4-(3, 4-methylenedioxyphenyl)butan-2-amine, distributed as MBDB. J Health Sci 2006, 52:805-810.
6. Takahashi M., Suzuki J., Nagashima M., Seto T., Yasuda I. Newly detected compounds in uncontrolled drugs purchased in Tokyo between April 2006 and March 2007. Ann Rep Tokyo Metr Inst Pub Health 2007, 58:83-87.
7. Kikura-Hanajiri R., Kawamura M., Saisho K., Kodama Y., Goda Y. The disposition into hair of new designer drugs; methylone, MBDB and methcathinone. J Chromatogr B 2007, 855:121-126.
8. Uchiyama N., Kikura-Hanajiri R., Kawahara N., Goda Y. Analysis of designer drugs detected in the products purchased in fiscal year 2006. Yakugaku Zasshi 2008, 128:1499-1505.
9. Kikura-Hanajiri R., Kawamura M., Uchiyama N., Ogata J., Kamakura H., Saisho K., et al. Analytical data of designated substances (Shitei-Yakubutsu) controlled by the pharmaceutical affairs law in Japan, part I: GC-MS and LC-MS. Yakugaku Zasshi 2008, 128:971-979.
10. Uchiyama N., Kawamura M., Kamakura H., Kikura-Hanajiri R., Goda Y. Analytical data of designated substances (Shitei-Yakubutsu) controlled by the pharmaceutical affairs law in Japan, part II: color test and TLC. Yakugaku Zasshi 2008, 128:981-987.
11. Nagashima M., Seto T., Takahashi M., Suzuki J., Mori K., Ogino S. Analyses of uncontrolled drugs purchased from April 2007 to March 2008 and newly found compounds. Ann Rep Tokyo Metr Inst Pub Health 2008, 59:71-77.
12. Uchiyama N., Miyazawa N., Kawamura M., Kikura-Hanajiri R., Goda Y. Analysis of newly distributed designer drugs detected in the products purchased in fiscal year 2008. Yakugaku Zasshi 2010, 130:263-270.
13. Nagashima M., Takahashi M., Suzuki J., Seto T., Mori K., Ogino S. Analyses of uncontrolled drugs purchased Apr. 2008-Mar. 2009. Ann Rep Tokyo Metr Inst Pub Health 2009, 60:81-84.
14. Kikura-Hanajiri R., Kawamura M., Miyajima A., Sunouchi M., Goda Y. Determination of a new designer drug, N-hydroxy-3,4-methylenedioxymethamphetamine and its metabolites in rats using ultra-performance liquid chromatography-tandem mass spectrometry. Forensic Sci Int 2010, 198:62-69.
15. Uchiyama N., Kikura-Hanajiri R., Kawahara N., Haishima Y., Goda Y. Identification of a cannabinoid analog as a new type of designer drug in a herbal product. Chem Pharm Bull 2009, 57:439-441.
16. Uchiyama N., Kikura-Hanajiri R., Kawahara N., Goda Y. Identification of a cannabimimetic indole as a designer drug in a herbal product. Forensic Toxicol 2009, 27:61-66.
17. Uchiyama N., Kikura-Hanajiri R., Ogata J., Goda Y. Chemical analysis of synthetic cannabinoids as designer drugs in herbal products. Forensic Sci Int 2010, 198:31-38.
18. Uchiyama N., Kawamura M., Kikura-Hanajiri R., Goda Y. Identification and quantitative analyses of two cannabimimetic phenylacetylindoles, JWH-251 and JWH-250, and four cannabimimetic naphthoylindoles, JWH-081, JWH-015, JWH-200 and JWH-073, as designer drugs in illegal products. Forensic Toxicol 2011, 29:25-37.
19. Nakajima J., Takahashi M., Seto T., Suzuki J. Identification and quantitation of cannabimimetic compound JWH-250 as an adulterant in products obtained via the internet. Forensic Toxicol 2011, 29:51-55.
20. Uchiyama N, Kikura-Hanajiri R, Shoda T, Fukuhara, K, Goda Y. Isomeric analysis of synthetic cannabinoids detected as designer drugs. Yakugaku Zasshi, submitted for publication.
21. Miyasaka K, Kawamura M, Uchiyama N, Kikura-Hanajiri R, Goda Y. Yakugaku Zasshi, Analytical data of synthetic cannabinoids distributed as psychotropic substances, Yakugaku Zasshi, submitted for publication.
22. Uchiyama N, Kikura-Hanajiri R, Goda Y. Identification of cannabimimetic lindoles as designer drugs in illegal products, in preparation.
23. Uchiyama N, Kikura-Hanajiri R, Goda Y. Analysis of newly distributed designer drugs-Cathinone derivatives-detected in products purchased in fiscal year 2010, in preparation.
24. EMCDDA action on new drugs briefing paper: understanding the 'Spice' phenomenon (a report from an EMCDDA expert meeting, 6 March 2009, Lisbon), updated version: 13 August 2009.
25. ACMD. Consideration of the cathinones, 2010.
26. ACMD. Consideration of the naphthylpyrovalerone analogs and related compounds, 2010.
27. EMCDDA-Europol 2009 Annual Report on the implementation of Council Decision 2005/387/JHA. In accordance with Article 10 of Council Decision 2005/387/JHA on the information exchange, risk-assessment and control of new psychoactive substances, 2010.
28. EMCDDA. Risk assessment report of a new psychoactive substance: 4-methylmethcathinone (mephedrone). In accordance with Article 6 of Council Decision 2005/387/JHA on information exchange, risk assessment and control of new psychoactive substances, 2010.
29. Official Journal of the European Union. Council decision of 2 December 2010 on submitting 4-methylmethcathinone (mephedrone) to control measures (2010/759/EU) 8.12.2010.
30. Auwärter V., Dresen S., Weinmann W., Müller M., Pütz M., Ferreirós N. 'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs?. J Mass Spectrom 2009, 44:832-837.
31. Compton D.R., Rice K.C., De Costa B.R., Razdan R.K., Melvin L.S., Johnson M.R., Martin B.R. Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J Pharmacol Exp Ther 1993, 265:218-226.
32. Huffman J.W. Cannabimimetic indoles, pyrroles, and indenes: structure-activity relationships and receptor interactions. The cannabinoid receptors 2009, 49-94. Humana Press, New York. P.H. Reggio (Ed.).
33. Lindigkeit R., Boehme A., Eiserloh I., Luebbecke M., Wiggermann M., Ernst L., et al. Spice: a never ending story?. Forensic Sci Int 2009, 191:58-63.
34. Dresen S., Ferreirós N., Pütz M., Westphal F., Zimmermann R., Auwärter V. Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds. J Mass Spectrom 2010, 45:1186-1194.
35. Compton D.R., Johnson M.R., Melvin L.S., Martin B.R. Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. J Pharmacol Exp Ther 1992, 260:201-209.
36. Melvin L.S., Milne G.M., Johnson M.R., Subramaniam B., Wilken G.H., Howlett A.C. Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs. Mol Pharmacol 1993, 44:1008-1015.
37. Thomas B.F., Compton D.R., Martin B.R. Characterization of the lipophilicity of natural and synthetic analogs of delta 9-tetrahydrocannabinol and its relationship to pharmacological potency. J Pharmacol Exp Ther 1990, 255:624-630.
38. Martin B.R., Compton D.R., Thomas B.F., Prescott W.R., Little P.J., Razdan R.K., et al. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem Behav 1991, 40:471-478.
39. Showalter V.M., Compton D.R., Martin B.R., Abood M.E. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 1996, 278:989-999.
40. 1 cannabinoid receptor. Bioorg Med Chem 2003, 11:539-549.
41. ACMD report on the major cannabinoid agonists: consideration of the major cannabinoid agonist, 2009.
42. 2 receptor binding. Drug Alcohol Depend 2000, 60:133-140.
43. Zweiundzwanzigste Verordnung, zur Änderung betäubungsmittelrechtlicher Vorschriften, Germany. BGBl I Nr. 3 vom 21.01.2009, 22. BtMÄndV vom 19. Januar 2009, S. 49-50.
44. Makriyannis A, Deng H. WO patent 200128557. Cannabimimetic indole derivatives, granted 2001-06-07.
45. Vardakou I., Pistos C., Spiliopoulou Ch. Spice drugs as a new trend: mode of action, identification and legislation. Toxicol Lett 2010, 197:157-162.
46. Glennon R.A., Yousif M., Naiman N., Kalix P. Methcathinone: a new and potent amphetamine-like agent. Pharmacol Biochem Behav 1987, 26:547-551.
47. Davies S., Wood D.M., Smith G., Button J., Ramsey J., Archer R., et al. Purchasing 'legal highs' on the Internet - is there consistency in what you get?. QJM 2010, 103:489-493.
48. Gibbons S., Zloh M. "Legal highs" on the net-Evaluation of UK-based Websites, products and product information. An analysis of the 'legal high' mephedrone. Bioorg Med Chem Lett 2010, 20:4135-4139.
49. Schmidt MM, Sharma A, Schifano F, Feinmann C, "Legal highs" on the net-Evaluation of UK-based Websites, products and product information. Forensic Sci Int 2010. doi:10.1016/j.forsciint.2010.06.030.
50. Brandt S.D., Sumnall H.R., Measham F., Cole J. Analyses of second-generation 'legal highs' in the UK: initial findings. Drug Test Anal 2010, 2:377-382.
51. Brandt SD, Freeman S, Sumnall HR, Measham F, Cole J. Analysis of NRG 'legal highs' in the UK: identification and formation of novel cathinones. Drug Test Anal 2010. doi:10.1002/dta.204.
52. Vardakou I, Pistos C, Spiliopoulou C. Drugs for youth via Internet and the example of mephedrone. Toxicol Lett 2010. doi:10.1016/j.toxlet.2010.12.014.
53. Wikström M., Thelander G., Nyström I., Kronstrand R. Two fatal intoxications with the new designer drug methedrone (4-methoxymethcathinone). J Anal Toxicol 2010, 34:594-598.
54. Springer D., Peters F.T., Fritschi G., Maurer H.H. Studies on the metabolism and toxicological detection of the new designer drug 4′-methyl-alpha-pyrrolidinopropiophenone in urine using gas chromatography-mass spectrometry. J Chromatogr B 2002, 773:25-33.
55. Foley K.F., Van Dort M.E., Sievert M.K., Ruoho A.E., Cozzi N.V. Stereospecific inhibition of monoamine uptake transporters by meta-hydroxyephedrine isomers. J Neural Transm 2002, 109:1229-1240.
56. Nagai F., Nonaka R., Satoh H., Kamimura K. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol 2007, 559:132-137.
57. Zaitsu K., Katagi M., Kamata H.T., Kamata T., Shima N., Miki A., et al. Determination of the metabolites of the new designer drugs bk-MBDB and bk-MDEA in human urine. Forensic Sci Int 2009, 188:131-139.
58. Hamano T., Shioda H., Nakajima J., Yasuda I. Analysis of psychotropic components in commercial botanical drugs. Ann Rep Tokyo Metr Inst Pub Health 2006, 57:121-126.
59. Kawamura M., Kikura-Hanajiri R., Goda Y. Survey of current trends in the abuse of psychotropic plants using LC-MS. Jpn J Food Chemistry 2008, 15:73-78.
60. Kawamura M., Kikura-Hanajiri R., Goda Y. Simple and rapid screening for psychotropic natural products using direct analysis in real time (DART)-TOFMS. Yakugaku Zasshi 2009, 129:719-725.
61. Maruyama T., Shirota O., Kawahara N., Yokoyama K., Makino Y., Goda Y. Discrimination of psychoactive fungi (commonly called "magic mushrooms") based on the DNA sequence of the internal transcribed spacer region. Shokuhin Eiseigaku Zasshi 2003, 44:44-48.
62. Maruyama T., Yokoyama K., Makino Y., Goda Y. Phylogenetic relationship of psychoactive fungi based on the rRNA gene for a large subunit and their identification using the TaqMan assay. Chem Pharm Bull 2003, 51:710-714.
63. Maruyama T., Kawahara N., Fukiharu T., Yokoyama K., Makino Y., Goda Y. DNA and chemical analyses of commercial fly agaric-related products. Shokuhin Eiseigaku Zasshi 2005, 46:49-54.
64. Maruyama T., Kawahara N., Yokoyama K., Makino Y., Fukiharu T., Goda Y. Phylogenetic relationship of psychoactive fungi based on rRNA gene for a large subunit and their identification using the TaqMan assay (II). Forensic Sci Int 2006, 163:51-58.
65. Maruyama T., Kamakura H., Kikura-Hanajiri R., Goda Y. Authentication and ultra performance liquid chromatography (UPLC)/MS analysis of magic mint, Salvia divinorum and its related plants. Yakugaku Zasshi 2008, 128:179-183.
66. Kikuchi H., Uchiyama N., Ogata J., Kikura-Hanajiri R., Goda Y. Chemical constituents and DNA sequence analysis of a psychotropic herbal product. Forensic Toxicol 2010, 28:1-7.
67. Kikura-Hanajiri R., Kawamura M., Maruyama T., Kitajima M., Takayama H., Goda Y. Simultaneous analysis of mitragynine, 7-hydroxymitragynine and other alkaloids in the psychotropic plant "Kratom" (Mitragyna speciosa) by LC-ESI-MS. Forensic Toxicol 2009, 27:67-74.
68. Maruyama M., Kawamura M., Kikura-Hanajiri R., Takayama H., Goda Y. The botanical origin of Kratom (Mitragyna speciosa; Rubiaceae) available as abused drugs in the Japanese markets. J Nat Med 2009, 63(3):340-344.
69. Kikura-Hanajiri R., Maruyama T., Miyashita A., Goda Y. Chemical and DNA analyses for the products of a psychoactive plant, Voacanga Africana. Yakugaku Zasshi 2009, 129:975-982.
70. Takayama H. Chemistry and pharmacology of analgesic indole alkaloids from the rubiaceous plant, Mitragyna speciosa. Chem Pharm Bull 2004, 52:916-928.
71. Stables J., Green A., Marshall F., Fraser N., Knight E., Sautel M., et al. A bioluminescent assay for agonist activity at potentially any G protein-coupled receptor. Anal Biochem 1997, 252:115-126.
72. Kitajima M, Iwai M, Kikura-Hanajiri R, Goda Y, Iida M, Yabushita H, Takayama H. Discovery of indole alkaloids with cannabinoid CB1 receptor antagonistic activity. Bioorg Med Chem Lett, accepted for publication.